메뉴 건너뛰기




Volumn 53, Issue 7, 2010, Pages 1258-1269

Erratum: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis (Diabetologia DOI: 10.1007/s00125-010-1702-3);Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

(16)  Schernthaner, G p   Barnett, A H a   Betteridge, D J b   Carmena, R c   Ceriello, A d   Charbonnel, B e   Hanefeld, M f   Lehmann, R g   Malecki, M T h   Nesto, R i   Pirags, V j   Scheen, A k   Seufert, J l   Sjoholm A m   Tsatsoulis, A n   DeFronzo, R o  


Author keywords

ADA consensus statement; Algorithm; Cardiovascular risk; EASD consensus statement; Glucose lowering therapy; Hyperglycaemia; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DIAMICRON MR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

EID: 77955657408     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1797-6     Document Type: Erratum
Times cited : (102)

References (102)
  • 1
    • 33745780301 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721.
    • (2006) Diabetologia , vol.49 , pp. 1711-1721
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 2
    • 57349160286 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30.
    • (2009) Diabetologia , vol.52 , pp. 17-30
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 3
    • 50049123766 scopus 로고    scopus 로고
    • Clinical practice recommendations 2008
    • American Diabetes Association
    • American Diabetes Association (2008) Clinical practice recommendations 2008. Diabetes Care 31:S1-S2.
    • (2008) Diabetes Care , vol.31
  • 4
    • 33845243126 scopus 로고    scopus 로고
    • Improving the use of research evidence in guideline development: 1. Guidelines for guidelines
    • WHO Advisory Committee on Health Research
    • Schünemann HJ, Fretheim A, Oxman AD, WHO Advisory Committee on Health Research (2006) Improving the use of research evidence in guideline development: 1. Guidelines for guidelines. Health Res Policy Syst 4:13.
    • (2006) Health Res Policy Syst , vol.4 , pp. 13
    • Schünemann, H.J.1    Fretheim, A.2    Oxman, A.D.3
  • 5
    • 55449095024 scopus 로고    scopus 로고
    • Development of evidence-based clinical practice guidelines (CPGs): Comparing approaches
    • Turner T, Misso M, Harris C, Green S (2008) Development of evidence-based clinical practice guidelines (CPGs): comparing approaches. Implement Sci 3:45.
    • (2008) Implement Sci , vol.3 , pp. 45
    • Turner, T.1    Misso, M.2    Harris, C.3    Green, S.4
  • 7
    • 3042651139 scopus 로고    scopus 로고
    • Grading quality of evidence and strength of recommendations
    • Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490.
    • (2004) BMJ , vol.328 , pp. 1490
    • Atkins, D.1    Best, D.2    Briss, P.A.3
  • 8
    • 63149173251 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2009
    • American Diabetes Association (ADA)
    • American Diabetes Association (ADA) (2009) Standards of medical care in diabetes-2009. Diabetes Care 32(Suppl 1): S13-S61.
    • (2009) Diabetes Care , vol.32 , Issue.SUPPL. 1
  • 9
    • 64649104158 scopus 로고    scopus 로고
    • From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus
    • DeFronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795.
    • (2009) Diabetes , vol.58 , pp. 773-795
    • DeFronzo, R.A.1
  • 10
    • 10344240901 scopus 로고    scopus 로고
    • Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial
    • behalf of the Quartet Study Group
    • Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, behalf of the Quartet Study Group (2004) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 6068-6076
    • Schernthaner, G.1    Matthews, D.R.2    Charbonnel, B.3    Hanefeld, M.4    Brunetti, P.5
  • 11
    • 16844371130 scopus 로고    scopus 로고
    • A longterm comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: A randomized, double-blind, parallelgroup comparison trial
    • behalf of the QUARTET Study Group
    • Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, behalf of the QUARTET Study Group (2005) A longterm comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallelgroup comparison trial. Diabet Med 22:399-405.
    • (2005) Diabet Med , vol.22 , pp. 399-405
    • Charbonnel, B.H.1    Matthews, D.R.2    Schernthaner, G.3    Hanefeld, M.4    Brunetti, P.5
  • 12
    • 33845405222 scopus 로고    scopus 로고
    • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
    • Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443.
    • (2006) N Engl J Med , vol.355 , pp. 2427-2443
    • Kahn, S.E.1    Haffner, S.M.2    Heise, M.A.3
  • 13
    • 34548609993 scopus 로고    scopus 로고
    • Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus
    • Bolen S, Wilson L, Vassy J et al (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399.
    • (2007) Ann Intern Med , vol.147 , pp. 386-399
    • Bolen, S.1    Wilson, L.2    Vassy, J.3
  • 14
    • 34447267513 scopus 로고    scopus 로고
    • Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
    • Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194-206.
    • (2007) JAMA , vol.298 , pp. 194-206
    • Amori, R.E.1    Lau, J.2    Pittas, A.G.3
  • 15
    • 69949163754 scopus 로고    scopus 로고
    • Exenatide and liraglutide: Different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results
    • Madsbad S (2009) Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 23:463-477.
    • (2009) Best Pract Res Clin Endocrinol Metab , vol.23 , pp. 463-477
    • Madsbad, S.1
  • 16
    • 52249111564 scopus 로고    scopus 로고
    • Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
    • Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008) Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 4:753-768.
    • (2008) Vasc Health Risk Manag , vol.4 , pp. 753-768
    • Richter, B.1    Bandeira-Echtler, E.2    Bergerhoff, K.3    Lerch, C.4
  • 17
    • 33846817233 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, doubleblind, non-inferiority trial
    • Sitagliptin Study 024 Group
    • Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab 9:194-205.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 194-205
    • Nauck, M.A.1    Meininger, G.2    Sheng, D.3    Terranella, L.4    Stein, P.P.5
  • 18
    • 58149330590 scopus 로고    scopus 로고
    • Fifty-two-week efficacy and safety of vildagliptin vs. Glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    • Ferrannini E, Fonseca V, Zinman B et al (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11:157-166.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 157-166
    • Ferrannini, E.1    Fonseca, V.2    Zinman, B.3
  • 19
    • 58549103962 scopus 로고    scopus 로고
    • Defining the role of basal and prandial insulin for optimal glycemic control
    • Horton ES (2009) Defining the role of basal and prandial insulin for optimal glycemic control. J Am Coll Cardiol 53(5 Suppl): S21-S27.
    • (2009) J Am Coll Cardiol , vol.53 , Issue.5 SUPPL.
    • Horton, E.S.1
  • 20
    • 69949134085 scopus 로고    scopus 로고
    • Optimal insulin regimens in type 2 diabetes mellitus: Systematic review and meta-analyses
    • Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ (2009) Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 52:1990-2000.
    • (2009) Diabetologia , vol.52 , pp. 1990-2000
    • Lasserson, D.S.1    Glasziou, P.2    Perera, R.3    Holman, R.R.4    Farmer, A.J.5
  • 21
    • 70350534273 scopus 로고    scopus 로고
    • Three-year efficacy of complex insulin regimens in type 2 diabetes
    • 4-T Study Group
    • Holman RR, Farmer AJ, Davies MJ, 4-T Study Group et al (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:1736-1747.
    • (2009) N Engl J Med , vol.361 , pp. 1736-1747
    • Holman, R.R.1    Farmer, A.J.2    Davies, M.J.3
  • 22
    • 47649100195 scopus 로고    scopus 로고
    • Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis
    • Monami M, Marchionni N, Mannucci E (2008) Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 81:184-189.
    • (2008) Diabetes Res Clin Pract , vol.81 , pp. 184-189
    • Monami, M.1    Marchionni, N.2    Mannucci, E.3
  • 23
    • 40949111213 scopus 로고    scopus 로고
    • Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial
    • Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073-1084.
    • (2008) Lancet , vol.371 , pp. 1073-1084
    • Bretzel, R.G.1    Nuber, U.2    Landgraf, W.3    Owens, D.R.4    Bradley, C.5    Linn, T.6
  • 24
    • 33845317568 scopus 로고    scopus 로고
    • Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride
    • Kann PH, Wascher T, Zackova V et al (2006) Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 114:527-532.
    • (2006) Exp Clin Endocrinol Diabetes , vol.114 , pp. 527-532
    • Kann, P.H.1    Wascher, T.2    Zackova, V.3
  • 25
    • 12844265257 scopus 로고    scopus 로고
    • Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs
    • Raskin P, Allen E, Hollander P et al (2005) Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260-265.
    • (2005) Diabetes Care , vol.28 , pp. 260-265
    • Raskin, P.1    Allen, E.2    Hollander, P.3
  • 26
    • 37449017989 scopus 로고    scopus 로고
    • Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison
    • Robbins DC, Beisswenger PJ, Ceriello A et al (2007) Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 29:2349-2364.
    • (2007) Clin Ther , vol.29 , pp. 2349-2364
    • Robbins, D.C.1    Beisswenger, P.J.2    Ceriello, A.3
  • 27
    • 38449093271 scopus 로고    scopus 로고
    • Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: An evidencebased comparison
    • Ilag LL, Kerr L, Malone JK, Tan MH (2007) Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidencebased comparison. Clin Ther 29 (Spec No):1254-1270.
    • (2007) Clin Ther , vol.29 , Issue.SPEC. NO. , pp. 1254-1270
    • Ilag, L.L.1    Kerr, L.2    Malone, J.K.3    Tan, M.H.4
  • 28
    • 57649230070 scopus 로고    scopus 로고
    • A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
    • Hollander P, Cooper J, Bregnhøj J, Pedersen CB (2008) A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 30:1976-1987.
    • (2008) Clin Ther , vol.30 , pp. 1976-1987
    • Hollander, P.1    Cooper, J.2    Bregnhøj, J.3    Pedersen, C.B.4
  • 29
    • 39049105019 scopus 로고    scopus 로고
    • A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes
    • Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G (2008) A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes. Diabetologia 51:408-416.
    • (2008) Diabetologia , vol.51 , pp. 408-416
    • Rosenstock, J.1    Davies, M.2    Home, P.D.3    Larsen, J.4    Koenen, C.5    Schernthaner, G.6
  • 30
    • 55949104933 scopus 로고    scopus 로고
    • 1c, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes
    • 1c, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. Int J Clin Pract 62:1935-1942.
    • (2008) Int J Clin Pract , vol.62 , pp. 1935-1942
    • Woo, V.1    Shestakova, M.V.2    Ørskov, C.3    Ceriello, A.4
  • 31
    • 70449450995 scopus 로고    scopus 로고
    • Medical antihyperglycaemic treatment of type 2 diabetes mellitus: Update of the evidence-based guideline of the German Diabetes Association
    • Matthaei S, Bierwirth R, Fritsche A et al (2009) Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 117: 522-557.
    • (2009) Exp Clin Endocrinol Diabetes , vol.117 , pp. 522-557
    • Matthaei, S.1    Bierwirth, R.2    Fritsche, A.3
  • 32
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865.
    • (1998) Lancet , vol.352 , pp. 854-865
  • 34
    • 0038279359 scopus 로고    scopus 로고
    • Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
    • Johnson JA, Majundar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248.
    • (2002) Diabetes Care , vol.25 , pp. 2244-2248
    • Johnson, J.A.1    Majundar, S.R.2    Simpson, S.H.3    Toth, E.L.4
  • 35
    • 33646422782 scopus 로고    scopus 로고
    • Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin
    • Evans JM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
    • (2006) Diabetologia , vol.49 , pp. 930-936
    • Evans, J.M.1    Ogston, S.A.2    Emslie-Smith, A.3    Morris, A.D.4
  • 36
    • 84860117993 scopus 로고    scopus 로고
    • Risk of cardiovascular disease and all cuase mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database
    • Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cuase mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731.
    • (2009) BMJ , vol.339
    • Tzoulaki, I.1    Molokhia, M.2    Curcin, V.3
  • 37
    • 0014914649 scopus 로고
    • A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetesm. II. Mortality results
    • Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetesm. II. Mortality results. Diabetes 19(Suppl):789-830.
    • (1970) Diabetes , vol.19 , Issue.SUPPL. , pp. 789-830
    • Meinert, C.L.1    Knatterud, G.L.2    Prout, T.E.3    Klimt, C.R.4
  • 38
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 39
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • The ADVANCE Collaborative Group
    • The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572.
    • (2008) N Engl J Med , vol.358 , pp. 2560-2572
  • 40
    • 0032895997 scopus 로고    scopus 로고
    • Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
    • Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr (1999) Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124.
    • (1999) J Am Coll Cardiol , vol.33 , pp. 119-124
    • Garratt, K.N.1    Brady, P.A.2    Hassinger, N.L.3    Grill, D.E.4    Terzic, A.5    Holmes Jr., D.R.6
  • 41
    • 0016410374 scopus 로고
    • A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy
    • The University Group Diabetes Program
    • The University Group Diabetes Program (1975) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 24(Suppl 1):65-184.
    • (1975) Diabetes , vol.24 , Issue.SUPPL. 1 , pp. 65-184
  • 42
    • 49649098865 scopus 로고    scopus 로고
    • Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
    • Rao AD, Kuhadiya N, Reynolds K, Fonseca VA (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 31:1672-1678.
    • (2008) Diabetes Care , vol.31 , pp. 1672-1678
    • Rao, A.D.1    Kuhadiya, N.2    Reynolds, K.3    Fonseca, V.A.4
  • 43
    • 29144453326 scopus 로고    scopus 로고
    • Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
    • Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653.
    • (2005) N Engl J Med , vol.353 , pp. 2643-2653
    • Nathan, D.M.1    Cleary, P.A.2    Backlund, J.Y.3
  • 44
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • Diabetes Control and Complications Trial Research Group
    • Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986.
    • (1993) N Engl J Med , vol.329 , pp. 977-986
  • 45
    • 0029147687 scopus 로고
    • Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
    • Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117.
    • (1995) Diabetes Res Clin Pract , vol.28 , pp. 103-117
    • Ohkubo, Y.1    Kishikawa, H.2    Araki, E.3
  • 46
    • 13444283628 scopus 로고    scopus 로고
    • Insulin treatment and cardiovascular disease; friend or foe? A point of view
    • Muis MJ, Bots ML, Grobbee DE, Stolk RP (2005) Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med 22:118-126.
    • (2005) Diabet Med , vol.22 , pp. 118-126
    • Muis, M.J.1    Bots, M.L.2    Grobbee, D.E.3    Stolk, R.P.4
  • 48
    • 34848884238 scopus 로고    scopus 로고
    • Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients
    • Kumar R, Lee TT, Jeremias A et al (2007) Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol 100:1187-1191.
    • (2007) Am J Cardiol , vol.100 , pp. 1187-1191
    • Kumar, R.1    Lee, T.T.2    Jeremias, A.3
  • 49
    • 50249179853 scopus 로고    scopus 로고
    • Association between serious ischemic cardiac outcomes and medications used to treat diabetes
    • Margolis DJ, Hoffstad O, Strom BL (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753-759.
    • (2008) Pharmacoepidemiol Drug Saf , vol.17 , pp. 753-759
    • Margolis, D.J.1    Hoffstad, O.2    Strom, B.L.3
  • 50
    • 38349133437 scopus 로고    scopus 로고
    • Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: A report from the Euro Heart Survey on Diabetes and the Heart
    • Euro Heart Survey Investigators
    • Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L, Euro Heart Survey Investigators (2008) Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29:177-184.
    • (2008) Eur Heart J , vol.29 , pp. 177-184
    • Anselmino, M.1    Ohrvik, J.2    Malmberg, K.3    Standl, E.4    Rydén, L.5
  • 51
    • 0033602795 scopus 로고    scopus 로고
    • Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study
    • Malmberg K, Norhammar A, Wedel H, Rydén L (1999) Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 99:2626-2632.
    • (1999) Circulation , vol.99 , pp. 2626-2632
    • Malmberg, K.1    Norhammar, A.2    Wedel, H.3    Rydén, L.4
  • 52
    • 20244384563 scopus 로고    scopus 로고
    • Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity
    • Malmberg K, Rydén L, Wedel H et al (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26:650-651.
    • (2005) Eur Heart J , vol.26 , pp. 650-651
    • Malmberg, K.1    Rydén, L.2    Wedel, H.3
  • 53
    • 38349094008 scopus 로고    scopus 로고
    • The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: A report from the DIGAMI 2 trial
    • for the DIGAMI 2 Investigators
    • Mellbin LG, Malmberg K, Norhammer A, Wedel H, Ryden L, for the DIGAMI 2 Investigators (2008) The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 29:166-176.
    • (2008) Eur Heart J , vol.29 , pp. 166-176
    • Mellbin, L.G.1    Malmberg, K.2    Norhammer, A.3    Wedel, H.4    Ryden, L.5
  • 54
    • 64749114318 scopus 로고    scopus 로고
    • Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial
    • Raz I, Wilson PW, Strojek K et al (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381-386.
    • (2009) Diabetes Care , vol.32 , pp. 381-386
    • Raz, I.1    Wilson, P.W.2    Strojek, K.3
  • 55
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitA-zone Clinical Trial In macroVascular Events): A randomised controlled trial
    • Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitA-zone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289.
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3
  • 57
    • 53349153475 scopus 로고    scopus 로고
    • Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
    • Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N (2008) Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 10:1221-1238.
    • (2008) Diabetes Obes Metab , vol.10 , pp. 1221-1238
    • Mannucci, E.1    Monami, M.2    Lamanna, C.3    Gensini, G.F.4    Marchionni, N.5
  • 58
    • 34548590934 scopus 로고    scopus 로고
    • Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
    • Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180-1188.
    • (2007) JAMA , vol.298 , pp. 1180-1188
    • Lincoff, A.M.1    Wolski, K.2    Nicholls, S.J.3    Nissen, S.E.4
  • 59
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471.
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 60
    • 34548580881 scopus 로고    scopus 로고
    • Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis
    • Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189-1195.
    • (2007) JAMA , vol.298 , pp. 1189-1195
    • Singh, S.1    Loke, Y.K.2    Furberg, C.D.3
  • 61
    • 35848930559 scopus 로고    scopus 로고
    • Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
    • Diamond GA, Bax L, Kaul S (2007) Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147:578-581.
    • (2007) Ann Intern Med , vol.147 , pp. 578-581
    • Diamond, G.A.1    Bax, L.2    Kaul, S.3
  • 62
    • 67149146438 scopus 로고    scopus 로고
    • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
    • Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135.
    • (2009) Lancet , vol.373 , pp. 2125-2135
    • Home, P.D.1    Pocock, S.J.2    Beck-Nielsen, H.3
  • 63
    • 35649003900 scopus 로고    scopus 로고
    • A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
    • Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 16: 1065-1071.
    • (2007) Pharmacoepidemiol Drug Saf , vol.16 , pp. 1065-1071
    • Gerrits, C.M.1    Bhattacharya, M.2    Manthena, S.3    Baran, R.4    Perez, A.5    Kupfer, S.6
  • 64
    • 50249169522 scopus 로고    scopus 로고
    • Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007
    • Walker AM, Koro CE, Landon J (2008) Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 17:760-768.
    • (2008) Pharmacoepidemiol Drug Saf , vol.17 , pp. 760-768
    • Walker, A.M.1    Koro, C.E.2    Landon, J.3
  • 65
    • 67650223772 scopus 로고    scopus 로고
    • GLP-1 therapy: Beyond glucose control
    • Hausenloy DJ, Yellon DM (2008) GLP-1 therapy: beyond glucose control. Circ Heart Fail 1:147-149.
    • (2008) Circ Heart Fail , vol.1 , pp. 147-149
    • Hausenloy, D.J.1    Yellon, D.M.2
  • 66
    • 58949084130 scopus 로고    scopus 로고
    • Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
    • Timmers L, Henriques JP, de Kleijn DP et al (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53:501-510.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 501-510
    • Timmers, L.1    Henriques, J.P.2    De Kleijn, D.P.3
  • 67
    • 64649102619 scopus 로고    scopus 로고
    • The GLP- 1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice
    • Noyan-Ashraf MH, Momen MA, Ban K et al (2009) The GLP- 1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes 58:975-983.
    • (2009) Diabetes , vol.58 , pp. 975-983
    • Noyan-Ashraf, M.H.1    Momen, M.A.2    Ban, K.3
  • 68
    • 34249682591 scopus 로고    scopus 로고
    • Beta-cell failure in diabetes and preservation by clinical treatment
    • Wajchenberg BL (2007) Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28:187-218.
    • (2007) Endocr Rev , vol.28 , pp. 187-218
    • Wajchenberg, B.L.1
  • 69
    • 33748748206 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial
    • The Dream (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
    • The Dream (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368:1096-1105.
    • (2006) Lancet , vol.368 , pp. 1096-1105
  • 70
    • 68949207969 scopus 로고    scopus 로고
    • Actos Now for the prevention of diabetes (ACT NOW) study
    • Defronzo RA, Banerji M, Bray GA et al (2009) Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord 29:9-17.
    • (2009) BMC Endocr Disord , vol.29 , pp. 9-17
    • Defronzo, R.A.1    Banerji, M.2    Bray, G.A.3
  • 71
    • 56149118663 scopus 로고    scopus 로고
    • Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy
    • Chen H-S, Wu T-E, Jap T-S, Hsiao L-C, Lee S-H, Lin H-D (2008) Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31:1927-1932.
    • (2008) Diabetes Care , vol.31 , pp. 1927-1932
    • Chen, H.-S.1    Wu, T.-E.2    Jap, T.-S.3    Hsiao, L.-C.4    Lee, S.-H.5    Lin, H.-D.6
  • 72
    • 43849105857 scopus 로고    scopus 로고
    • Effect of intensive insulin therapy on β-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial
    • Weng J, Li Y, Xu W et al (2008) Effect of intensive insulin therapy on β-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371:1753-1760.
    • (2008) Lancet , vol.371 , pp. 1753-1760
    • Weng, J.1    Li, Y.2    Xu, W.3
  • 73
    • 38549162147 scopus 로고    scopus 로고
    • Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    • Klonoff DC, Buse JB, Nielsen LL et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275-286.
    • (2008) Curr Med Res Opin , vol.24 , pp. 275-286
    • Klonoff, D.C.1    Buse, J.B.2    Nielsen, L.L.3
  • 74
    • 65949122087 scopus 로고    scopus 로고
    • One-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: A randomized, controlled trial
    • Bunck MC, Diamant M, Corner A et al (2009) One-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial. Diabetes Care 32:762-768.
    • (2009) Diabetes Care , vol.32 , pp. 762-768
    • Bunck, M.C.1    Diamant, M.2    Corner, A.3
  • 75
    • 33846414720 scopus 로고    scopus 로고
    • Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary
    • The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    • Rydén L, Standl E, Bartnik M et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88-136.
    • (2007) Eur Heart J , vol.28 , pp. 88-136
    • Rydén, L.1    Standl, E.2    Bartnik, M.3
  • 76
    • 1242273636 scopus 로고    scopus 로고
    • The effects of oral anti-hyperglycemic medications on serum lipid profiles in patients with type 2 diabetes
    • Buse JB, Tan MH, Prince MJ, Erickson PP (2004) The effects of oral anti-hyperglycemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 6:133-156.
    • (2004) Diabetes Obes Metab , vol.6 , pp. 133-156
    • Buse, J.B.1    Tan, M.H.2    Prince, M.J.3    Erickson, P.P.4
  • 77
    • 7044253431 scopus 로고    scopus 로고
    • A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
    • Chiquette E, Ramirez G, DeFronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097-2104.
    • (2004) Arch Intern Med , vol.164 , pp. 2097-2104
    • Chiquette, E.1    Ramirez, G.2    DeFronzo, R.3
  • 78
    • 34547901744 scopus 로고    scopus 로고
    • Effects of pioglitazone on lipid and lipoprotein metabolism
    • Betteridge DJ (2007) Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 9:640-647.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 640-647
    • Betteridge, D.J.1
  • 79
    • 33845400193 scopus 로고    scopus 로고
    • Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial
    • Mazzone T, Meyer PM, Feinstein SB et al (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572-2581.
    • (2006) JAMA , vol.296 , pp. 2572-2581
    • Mazzone, T.1    Meyer, P.M.2    Feinstein, S.B.3
  • 80
    • 41649084422 scopus 로고    scopus 로고
    • Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial
    • Nissen SE, Nicholls SJ, Wolski K et al (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299: 1561-1573.
    • (2008) JAMA , vol.299 , pp. 1561-1573
    • Nissen, S.E.1    Nicholls, S.J.2    Wolski, K.3
  • 82
    • 33745000699 scopus 로고    scopus 로고
    • Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients
    • Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G (2006) Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29:554-559.
    • (2006) Diabetes Care , vol.29 , pp. 554-559
    • Rosenstock, J.1    Sugimoto, D.2    Strange, P.3    Stewart, J.A.4    Soltes-Rak, E.5    Dailey, G.6
  • 83
    • 33845478593 scopus 로고    scopus 로고
    • Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea
    • Triplitt C, Glass L, Miyazaki Y et al (2006) Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 29:2371-2377.
    • (2006) Diabetes Care , vol.29 , pp. 2371-2377
    • Triplitt, C.1    Glass, L.2    Miyazaki, Y.3
  • 84
    • 33746690405 scopus 로고    scopus 로고
    • Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
    • Matikainen N, Mänttäri S, Schweizer A et al (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049-2057.
    • (2006) Diabetologia , vol.49 , pp. 2049-2057
    • Matikainen, N.1    Mänttäri, S.2    Schweizer, A.3
  • 85
    • 65649084066 scopus 로고    scopus 로고
    • Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
    • Schernthaner G (2009) Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 63:912-929.
    • (2009) Int J Clin Pract , vol.63 , pp. 912-929
    • Schernthaner, G.1
  • 86
    • 48349116165 scopus 로고    scopus 로고
    • Metformin: Effects on micro and macrovascular complications in type 2 diabetes
    • Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22:215-224.
    • (2008) Cardiovasc Drugs Ther , vol.22 , pp. 215-224
    • Bailey, C.J.1
  • 87
    • 0035140430 scopus 로고    scopus 로고
    • Rosiglitazone monotherapy is effective in patients with type 2 diabetes
    • The Rosiglitazone Clinical Trials Study Group
    • Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, The Rosiglitazone Clinical Trials Study Group (2001) Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 280-288
    • Lebovitz, H.E.1    Dole, J.F.2    Patwardhan, R.3    Rappaport, E.B.4    Freed, M.I.5
  • 88
    • 0036072223 scopus 로고    scopus 로고
    • Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients
    • Miyazaki Y, Mahankali A, Matsuda M et al (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 2784-2791
    • Miyazaki, Y.1    Mahankali, A.2    Matsuda, M.3
  • 89
    • 0027935577 scopus 로고
    • Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study
    • Hermann LS, Schersten B, Bitzen PO, Kjellström T, Lindgärde F, Melander A (1994) Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 17:1100-1109.
    • (1994) Diabetes Care , vol.17 , pp. 1100-1109
    • Hermann, L.S.1    Schersten, B.2    Bitzen, P.O.3    Kjellström, T.4    Lindgärde, F.5    Melander, A.6
  • 90
    • 37849035246 scopus 로고    scopus 로고
    • Weighing up the cardiovascular benefits of thiazolidinedione therapy: The impact of increased risk of heart failure
    • Erdmann E, Wilcox RG (2008) Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 29:12-20.
    • (2008) Eur Heart J , vol.29 , pp. 12-20
    • Erdmann, E.1    Wilcox, R.G.2
  • 91
    • 34548603259 scopus 로고    scopus 로고
    • Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review
    • Eurich DT, McAlister FA, Blackburn DF et al (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335:497-501.
    • (2007) BMJ , vol.335 , pp. 497-501
    • Eurich, D.T.1    McAlister, F.A.2    Blackburn, D.F.3
  • 92
    • 67649298019 scopus 로고    scopus 로고
    • Risk of fractures with glitazones: A critical review of the evidence to date
    • Bodmer M, Meier C, Kraenzlin ME, Meier CR (2009) Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 32:539-547.
    • (2009) Drug Saf , vol.32 , pp. 539-547
    • Bodmer, M.1    Meier, C.2    Kraenzlin, M.E.3    Meier, C.R.4
  • 93
    • 59349101451 scopus 로고    scopus 로고
    • information (18 August 2008 update), Available from, accessed 16 January 2010
    • US Food and Drug Administration (2008) Exenatide (marketed as Byetta) information (18 August 2008 update). Available from www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm, accessed 16 January 2010.
    • (2008) Exenatide (Marketed as Byetta)
  • 94
    • 77955658849 scopus 로고    scopus 로고
    • information (issued 25 September 2009), Available from, accessed 16 January 2010
    • U.S. Food and Drug Administration (2008) Sitagliptin (marketed as Januvia and Janumet) information (issued 25 September 2009). Available from www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm183768.htm, accessed 16 January 2010.
    • (2008) Sitagliptin (Marketed as Januvia and Janumet)
  • 95
  • 96
    • 67649304917 scopus 로고    scopus 로고
    • Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
    • Dore DD, Seeger JD, Arnold Chan K (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25:1019-1027.
    • (2009) Curr Med Res Opin , vol.25 , pp. 1019-1027
    • Dore, D.D.1    Seeger, J.D.2    Arnold, C.K.3
  • 98
    • 69549097703 scopus 로고    scopus 로고
    • New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes
    • Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625.
    • (2009) Diabetes Care , vol.32 , pp. 1620-1625
    • Libby, G.1    Donnelly, L.A.2    Donnan, P.T.3    Alessi, D.R.4    Morris, A.D.5    Evans, J.M.6
  • 99
    • 68449094325 scopus 로고    scopus 로고
    • The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    • Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777.
    • (2009) Diabetologia , vol.52 , pp. 1766-1777
    • Currie, C.J.1    Poole, C.D.2    Gale, E.A.3
  • 100
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • The Action to Control Cardiovascular Risk in Diabetes Study Group
    • The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559.
    • (2008) N Engl J Med , vol.358 , pp. 2545-2559
  • 101
    • 75749145810 scopus 로고    scopus 로고
    • 1c in people with type 2 diabetes: A retrospective cohort study
    • 1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481-489.
    • (2010) Lancet , vol.375 , pp. 481-489
    • Currie, C.J.1    Peters, J.R.2    Tynan, A.3
  • 102
    • 59449094308 scopus 로고    scopus 로고
    • Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Woo V (2009) Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:552-553.
    • (2009) Diabetologia , vol.52 , pp. 552-553
    • Woo, V.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.